Lifestance Health Group, INC 8-K filings

LifeStance Health Group announces immediate resignation of director Jeffrey Rhodes and appoints three new board members, Thurman Justice, Lori Goltermann, and Safwan Shabab.

LifeStance Health Group, Inc. reports the successful election of directors and ratification of auditors at its 2026 annual meeting.

LifeStance Health Group, Inc. has entered into an underwriting agreement for the sale of 35 million shares of common stock by selling stockholders.

LifeStance Health Group, Inc. announced an underwritten secondary offering of 25 million common shares by selling stockholders, with the company repurchasing 7 million of those shares.

LifeStance Health Group announced robust fourth quarter and full year 2025 financial results, including double-digit revenue growth and positive net income, alongside a new $100 million share repurchase program.

LifeStance Health Group, a leading mental healthcare provider, announced record third-quarter 2025 financial results, including positive net income and raised full-year guidance.

LifeStance Health Group announced the resignation of William Miller from its board and the immediate appointment of Sarah Personette as a new director.

LifeStance Health Group, a leading mental healthcare provider, announced robust second-quarter 2025 financial results, exceeding expectations with double-digit revenue and Adjusted EBITDA growth, and raising full-year guidance.

LifeStance Health Group, Inc. announced that its stockholders approved all proposals at the annual meeting on June 3, 2025, including the election of three Class I directors, the ratification of PricewaterhouseCoopers LLP as its independent auditor, and the advisory approval of named executive officer compensation.

LifeStance Health announces the appointment of Vaughn Paunovich as its new Chief Technology Officer, effective June 9, 2025, while Chief Digital Officer Pablo Pantaleoni will depart on July 1, 2025.

LifeStance Health Group announced its Q1 2025 financial results, highlighting revenue growth, increased clinician base, and positive net income for the first time as a public company.

LifeStance Health Group appoints Dave Bourdon as the new CEO, succeeding Ken Burdick who will become Executive Chairman, and names Ryan McGroarty as the new CFO.

LifeStance Health Group announces a 16% increase in fourth-quarter revenue and a 19% increase in full-year revenue, driven by clinician growth and improved visit volumes.

LifeStance Health Group has entered into a new credit agreement, securing a $290 million term loan and a $100 million revolving credit facility, while terminating its previous credit agreement.

LifeStance Health Group reported strong third-quarter results, surpassing expectations and raising its full-year 2024 revenue and profitability guidance.

LifeStance Health Group reported strong second-quarter results, exceeding expectations with a 20% revenue increase and a significant jump in adjusted EBITDA, leading to raised full-year guidance.

LifeStance Health Group's President and Chief Operating Officer, Danish Qureshi, has departed effective June 30, 2024, with a separation agreement in place.

LifeStance Health Group held its annual meeting on June 3, 2024, where stockholders elected directors, ratified the accounting firm, and approved executive compensation matters.

LifeStance Health Group, Inc. has entered into an underwriting agreement for a 20 million share offering of its common stock by existing selling stockholders, with an option for underwriters to purchase an additional 3 million shares.

LifeStance Health Group announced a 19% increase in revenue and a significant improvement in adjusted EBITDA for the first quarter of 2024, leading to an increased full-year outlook.

LifeStance Health Group has appointed Teresa DeLuca as a new member of its Board of Directors, effective immediately on March 12, 2024.

LifeStance Health Group announced a 23% increase in full-year revenue for 2023 and projects continued growth and positive free cash flow in 2024.

LifeStance Health has completed a $50 million settlement and disclosed preliminary financial information for the fourth quarter of 2023, ending the year with $79 million in cash and $290 million in long-term debt.